Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C10H8O3.H2O |
| Molecular Weight | 194.184 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O.CC1=CC(=O)OC2=CC(O)=CC=C12
InChI
InChIKey=HRFJWEHVFMYQSS-UHFFFAOYSA-N
InChI=1S/C10H8O3.H2O/c1-6-4-10(12)13-9-5-7(11)2-3-8(6)9;/h2-5,11H,1H3;1H2
| Molecular Formula | C10H8O3 |
| Molecular Weight | 176.1687 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | H2O |
| Molecular Weight | 18.0153 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Hymecromone (4-methylumbelliferone) is already approved drug in Europe and Asia where it is used to treat biliary spasm. It is used as choleretic and antispasmodic drugs and as a standard for the fluorometric determination of enzyme activity. The concomitant administration of Hymecromone with products, containing metoclopramide, leads to mutual decrease of their action. Due to a danger of diarrhea with subsequent hypokalemia, Hymecromone should be applied with caution to patients on cardiac glycosides therapy (in these cases the sensitivity to them is increased). Hymecromone can be administered simultaneously with otherspasmolytics and analgesics. Very rare allergic reactions, itching, erythema, rashes; diarrhea which normally disappears by reduction of dose or discontinuance of therapy.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Deglucuronidation of a flavonoid, luteolin monoglucuronide, during inflammation. | 2001 Dec |
|
| [Effects of 18 alpha-glycyrrhizic acid on rat liver cytochrome P450 isoenzymes and phase II transferase]. | 2001 May |
|
| A fluorimetric enzyme assay for the diagnosis of MPS II (Hunter disease). | 2001 Nov |
|
| High beta-galactosidase and ganglioside GM1 levels in the human parotid gland. | 2001 Nov |
|
| A fluorogenic assay using pressure-driven flow on a microchip. | 2001 Oct |
|
| [Dysfunction of the Oddi's sphincter]. | 2001 Sep |
|
| Development of an enzyme assay for rapid assessment of Escherichia coli in seawaters. | 2002 |
|
| Some coumarins and triphenylethene derivatives as inhibitors of human testes microsomal 17beta-hydroxysteroid dehydrogenase (17beta-HSD type 3): further studies with tamoxifen on the rat testes microsomal enzyme. | 2002 Apr |
|
| A sulfated proteoglycan is necessary for storage of exocrine secretory proteins in the rat parotid gland. | 2002 Aug |
|
| Expression of active human beta-glucuronidase in Sf9 cells infected with recombinant baculovirus. | 2002 Aug 16 |
|
| Protection against damaged DNA in the single cell by polyphenols. | 2002 Dec |
|
| Optimisation of an enzymatic method for beta-galactosidase. | 2002 Dec |
|
| Persistence and degradation of coumaphos in model cattle dipping vats. | 2002 Jan |
|
| Pharmacokinetic analysis of factors determining elimination pathways for sulfate and glucuronide metabolites of drugs. I: studies by in vivo constant infusion. | 2002 May |
|
| Tissue-specific regulation of canine intestinal and hepatic phenol and morphine UDP-glucuronosyltransferases by beta-naphthoflavone in comparison with humans. | 2002 May 1 |
|
| The importance of cysteine 126 in the human liver UDP-glucuronosyltransferase UGT1A6. | 2002 May 20 |
|
| Stereoselective conjugation of oxazepam by human UDP-glucuronosyltransferases (UGTs): S-oxazepam is glucuronidated by UGT2B15, while R-oxazepam is glucuronidated by UGT2B7 and UGT1A9. | 2002 Nov |
|
| A colorimetric and fluorometric microplate assay for the detection of microcystin-LR in drinking water without preconcentration. | 2002 Nov |
|
| 4-Methylumbelliferone induces the expression of membrane type 1-matrix metalloproteinase in cultured human skin fibroblasts. | 2002 Nov 15 |
|
| Metabolizing enzyme localization and activities in the first trimester human placenta: the effect of maternal and gestational age, smoking and alcohol consumption. | 2002 Oct |
|
| Effects of bergamottin on human and monkey drug-metabolizing enzymes in primary cultured hepatocytes. | 2002 Sep |
|
| A 45-kDa midgut glycoprotein from Anopheles albimanus mosquito mediates the killing of trypanosomes. | 2002 Sep |
|
| [Effect of vegetotropic pharmacologic preparations of the motor-evacuatory function of the gallbladder in patients with chronic biliary tract pathology]. | 2003 |
|
| Aryl sulfatase from Naja nigricolis venom: characterization and possible contribution in the pathology of snake poisoning. | 2003 |
|
| Polar organic solvent added to an aqueous solution changes hydrolytic property of lipase. | 2003 Aug |
|
| Verapamil regulates activity and mRNA-expression of human beta-glucuronidase in HepG2 cells. | 2003 Dec |
|
| Kinetic studies on the hydrolysis of N-acetylated and N-deacetylated derivatives of 4-methylumbelliferyl chitobioside by the family 18 chitinases ChiA and ChiB from Serratia marcescens. | 2003 Feb |
|
| Microtiter plate cellular assay for human steroid sulfatase with fluorescence readout. | 2003 Jul 15 |
|
| Development of fluorescence-based selective assays for serine/threonine and tyrosine phosphatases. | 2003 Jun |
|
| Detection and characterization of a novel extracellular fungal enzyme that catalyzes the specific and hydrolytic cleavage of lignin guaiacylglycerol beta-aryl ether linkages. | 2003 Jun |
|
| Cloning and characterization of two alpha-glucosidases from Bifidobacterium adolescentis DSM20083. | 2003 Mar |
|
| Highly sensitive active-site titration of lipase in microscale culture media using fluorescent organophosphorus ester. | 2003 Mar 17 |
|
| Solid-phase peptide synthesis by ion-paired alpha-chymotrypsin in nonaqueous media. | 2003 Mar 30 |
|
| Pharmacokinetic analysis of factors determining elimination pathways for sulfate and glucuronide metabolites of xenobiotics II: Studies with isolated perfused rat liver. | 2003 Nov |
|
| Cloning and expression of alpha-D-glucosidase and N-acetyl-beta-glucosaminidase from the periodontal pathogen, Tannerella forsythensis (Bacteroides forsythus). | 2003 Oct |
|
| Induction of rat hepatic and intestinal UDP-glucuronosyltransferases by naturally occurring dietary anticarcinogens. | 2003 Oct |
|
| Inhibition of influenza A virus sialidase activity by sulfatide. | 2003 Oct 23 |
|
| Biochemical and catalytic properties of an endoxylanase purified from the culture filtrate of Sporotrichum thermophile. | 2003 Sep 1 |
|
| Structural requirements of hydroxylated coumarins for in vitro anti-Helicobacter pylori activity. | 2003 Sep-Oct |
|
| Mechanism of the hydrolysis of 4-methylumbelliferyl-beta-D-glucoside by germinating and outgrowing spores of Bacillus species. | 2004 |
|
| DNA damage in healthy term neonate. | 2004 Apr |
|
| Human udp-glucuronosyltransferases: isoform selectivity and kinetics of 4-methylumbelliferone and 1-naphthol glucuronidation, effects of organic solvents, and inhibition by diclofenac and probenecid. | 2004 Apr |
|
| Susceptibility of human influenza viruses from Australasia and South East Asia to the neuraminidase inhibitors zanamivir and oseltamivir. | 2004 Apr |
|
| Development of novel conductometric biosensors based on immobilised whole cell Chlorella vulgaris microalgae. | 2004 Apr 15 |
|
| Molecular characterization of membrane type and ganglioside-specific sialidase (Neu3) expressed in E. coli. | 2004 Apr 30 |
|
| Identification of aryl-phospho-beta-D-glucosidases in Bacillus subtilis. | 2004 Jan |
|
| Stability of the complexes of some lanthanides with coumarin derivatives. I. Cerium(III)-4-methyl-7-hydroxycoumarin. | 2004 Mar |
|
| Effects of dietary anticarcinogens and nonsteroidal anti-inflammatory drugs on rat gastrointestinal UDP-glucuronosyltransferases. | 2004 Mar-Apr |
|
| Aldehyde detection by chromogenic/fluorogenic oxime bond fragmentation. | 2004 May 21 |
|
| A novel efflux-recapture process underlies the mechanism of high-density lipoprotein cholesteryl ester-selective uptake mediated by the low-density lipoprotein receptor-related protein. | 2004 Sep |
Sample Use Guides
1 tablet 3 times daily during basic meals. The tablets are administered unchewed with a liquid.
Route of Administration:
Oral
4-Methylumbelliferone (4-MU/HYMECROMONE) inhibits hyaluronan synthesis and retards cancer spreading in experimental animals through mechanisms not fully understood. These mechanisms were studied in A2058 melanoma cells, MCF-7 and MDA-MB-361 breast, SKOV-3 ovarian and UT-SCC118 squamous carcinoma cells by analysing hyaluronan synthesis, UDP-glucuronic acid (UDP-GlcUA) content, and hyaluronan synthase (HAS) mRNA levels. The maximal inhibition in hyaluronan synthesis ranged 22-80% in the cell lines tested. Active glucuronidation of 4-MU produced large quantities of 4-MU-glucuronide, depleting the cellular UDP-GlcUA pool. The maximal reduction varied between 38 and 95%. 4-MU also downregulated HAS mRNA levels: HAS3 was 84-60% lower in MDA-MB-361, A2058 and SKOV-3 cells.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Tue Oct 22 12:36:54 UTC 2019
by
admin
on
Tue Oct 22 12:36:54 UTC 2019
|
| Record UNII |
ORG176G874
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
103764-33-6
Created by
admin on Tue Oct 22 12:36:54 UTC 2019 , Edited by admin on Tue Oct 22 12:36:54 UTC 2019
|
PRIMARY | |||
|
60196415
Created by
admin on Tue Oct 22 12:36:54 UTC 2019 , Edited by admin on Tue Oct 22 12:36:54 UTC 2019
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
